期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

(3R,5S,6E)-7-(4-对氟苯硫基-6,7,8-三氟喹啉-3-基)-3,5-二羟基庚烯酸钙有关物质的合成 被引量：1

Synthesis of the Related Substances of Calcium(3R,5S,6E)-7-[4-(4-Fluorophenylthio)-6,7,8-trifluoroquinolin-3-yl]-3,5-dihydroxyheptenoate
原文传递
导出
摘要 为加强对降血脂候选药物(3R,5S,6E)-7-(4-对氟苯硫基-6,7,8-三氟喹啉-3-基)-3,5-二羟基庚烯酸钙(2)的质量控制,合成了可能存在于药品中的5个有关物质:(3R,6E)-7-(4-对氟苯硫基-6,7,8-三氟喹啉-3-基)-3-羟基-5-氧代庚烯酸(3)、(3R,5S,6E)-7-(4-对氟苯亚磺酰基-6,7,8-三氟喹啉-3-基)-3,5-二羟基庚烯酸(4)、(3R,5S,6Z)-7-(4-对氟苯硫基-6,7,8-三氟喹啉-3-基)-3,5-二羟基庚烯酸(5)、(3R,5R,6E)-7-(4-对氟苯硫基-6,7,8-三氟喹啉-3-基)-3,5-二羟基庚烯酸(6),以及(3R*,5S*,6E)-7-(4-对氟苯硫基-6,7,8-三氟喹啉-3-基)-3,5-二羟基庚烯酸(7)。 Five related substances of calcium（3R,5S,6E）-7-[4-（4-fluorophenylthio）-6,7,8-trifluoroquinolin- 3-yl]-3,5-dihydroxyheptenoate（2）which is in extensively preclinical investigation as an anti-hypercholesterolemic drug candidate,were synthesized and may be served as references in the quality control of 2.They were（3R,6E） - 7-[4-（4-fluorophenylthio）-6,7,8-trifluoroquinolin-3-yl]-3-hydroxy-5-oxoheptenoic acid（3）,（3R,5S,6E）-7- [4-（4-fluorophenylsulfinyl）-6,7,8-trifluoroquinolin-3-yl]-3,5-dihydroxyheptenoic acid（4）,（3R,5S,6Z）-7-[4- （4-fluorophenylthio）-6,7,8-trifluoroquinolin-3-yl]-3,5-dihydroxyheptenoic acid（5）,（3R,5R,6E）-7-[4-（4- fluorophenylthio）-6,7,8-trifluoroquinolin-3-yl]-3,5-dihydroxyheptenoic acid（6）,and（3R~＊,5S~＊,6E）-7-[4-（4- fluorophenylthio） -6,7,8-trifluoroquinolin-3-yl]-3,5-dihydroxyheptenoic acid（7）.
作者 郝群 蔡正艳 潘竞 李泳佳 周伟澄
机构地区 上海医药工业研究院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2010年第12期884-890,共7页 Chinese Journal of Pharmaceuticals
基金 国家“重大新药创制”科技重大专项(2009ZX09301-007) 上海创新行动计划(09431901300)
关键词 降血脂药物 HMG COA还原酶抑制剂 有关物质 合成 anti-hypercholesterolemic drug HMG CoA reductase inhibitor related substance synthesis
分类号 O626 [理学—有机化学]
  • 相关文献

参考文献12

  • 1MaronDJ FazioS LintonMF.Current perspectives on statins.Circulation,2000,101(2):207-213.
  • 2Cai Z,Zhou W,Sun L.Synthesis and HMG CoA reductase inhibition of 4-thiophenyl quinolines as potential hypocholesterolcmic agents[J].Bioorg Med Chem,2007,15 (24):7809-7829.
  • 3Cai Z,Zhou W,Pan J,et al.Synthesis of 4-phenoxy quinoline mevalonolactones and evaluation of their HMG CoA reductase inhibition activities[J].J Chin Pharma Sci,2010,19:15-23.
  • 4Hao Q,Cai Z,Pan J,et al.Synthesis and anti-hypercholesterolemic evaluations of calcium salts of 4-substituted quinolihe-based mevaionic acid[J].Chem Biol Drug Des,待发表.
  • 5蔡正艳,周伟澄,郝群,等.喹啉类化合物及其药物组合物、制备方法和应用:中国,101570510A[P].2009-11-04.
  • 6蔡正艳,周伟澄.匹伐他汀钙的合成[J].中国医药工业杂志,2007,38(3):177-180. 被引量：9
  • 7Tempkin O,Abel S,Chen CP,et al.Asymmetric synthesis of 3,5-dihydroxy-6 (E) -heptenoate-containing HMG-CoA reductase inhibitors[J].Tetrahedron,1997,53 (31):10659-10670.
  • 8Evans DA,Chapman KT,Carreira EM.Directed reduction of β-hydroxy ketones employing tetramethylammonium triacetoxyborohydride[J].J Am Chem Soc,1988,110(11):3560-3578.
  • 9Suzuki M,Iwasaki H,Fujikawa Y,et al.Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors[J].Bioorg Med Chem,2001,9 (10):2727-2743.
  • 10Sliskovic DR,Picard JA,Roark WH,et al.Inhibitors of cholesterol biosynthesis.4.trans-6-[2-(Substituted-quinolinyl) ethenyl/ethyl] tctrahydro-4-hydroxy-2H-pyran-2-ones,a novel series of HMG-CoA reductase inhibitors[J].JMed Chem,1991,34 (1):367-373.

二级参考文献12

  • 1蔡正艳,宁奇,周伟澄.HMG-CoA还原酶抑制剂的合成(下)[J].中国医药工业杂志,2004,35(11):687-691. 被引量：5
  • 2Chen KM, Hardtmann GE, Lee GT, et al. Preparation of olefinic compounds: EP, 244364 [P]. 1987-11-04. (CA 1987,108:131038)．
  • 3Kathawala FG, Lakes N J. Intermediates in the synthesis indole analogs of mevalonolactone and derivatives thereof: US, 4739073 [P]. 1988-04-19; WO, 8402131 [P]. 1984-06-07.(CA 1984, 102: 24475)．
  • 4Istituto Chemioterapico. Method of preparing β-amino-acroleins: GB, 945536[P]. 1964-01-02. (CA 1964, 60:60474).
  • 5Lee GT, Amedio JC Jr, Underwood R, et al. Vinylformylation utilizing propeniminium salts [J]. J Org Chem, 1992, 57(11): 3250-3252.
  • 6Aoki T,Nishimura H,Nakagawa S,et al.Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase[J].Arzneim-Forsch DrugRes,1997,47:904-909.
  • 7Miyachi N,Yanagawa Y,lwasaki H,et al.A novel synthetic method of HMG-CoA reductase inhibitor NK-104 via a hydroboration-cross coupling sequence[J].Tetrahedron Left,1993,34(51):8267-8270.
  • 8Fujikawa Y,Suzuki M,Iwasaki H,et al.Quinoline type mevalonolactones:EP,304063[P].1989-02-22.(CA 1989,111:134010)
  • 9Wess G,Kesseler K,Baader E,et al.stereoselective synthesis of HR 780 a new highly potent HMG-CoA reductase inhibitor[J].Tetrahrdron Lett,1990,31(18):2545-2548.
  • 10Hyama T,Minami T,Yanagawa E,et al.Preparation of pyridine-type mevalonolactone intermediates:JP,53 10700[P].1993-11-22.(CA 1994,120:244704)

共引文献11

同被引文献4

  • 1谢沐风.如何建立高效液相色谱法测定有关物质的方法[J].中国医药工业杂志,2007,38(1):45-48. 被引量：61
  • 2Cai Z,Zhou W,Sun L. Synthesis and HMG CoA reductase inhibition of 4-thiophenyl quinolines as potential hypocholesterolemic agents[J].Bioorganic and Medicinal Chemistry Letters,2007,(24):7809-7829.
  • 3Cai Z,Zhou W,Pan J. Synthesis of4-phenoxy quinoline mevalonolactones and evaluation of their HMG CoA reductase inhibition activities[J].J Chin Pharmaceu Sci,2010,(01):15-23.
  • 4Hao Q,Cai Z,Pan J. Synthesis and anti-hypercholesterolemic evaluations of calcium salts of 4-substituted quinolinebased mevalonic acid[J].CHEMICAL BIOLOGY & DRUG DESIGN,2011,(04):730-733.

引证文献1

中国医药工业杂志
2010年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部